[Comment] Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors

The Bruton's tyrosine kinase (BTK) protein is a crucial component of antigen-dependent B-cell receptor signalling that regulates B-cell development and maturation. BTK is also implicated in major processes of malignant B non-Hodgkin lymphoma (NHL-B) and chronic lymphocytic leukaemia (CLL) cells such as proliferation, survival, and trafficking. BTK inhibition has a profound effect on malignant cell survival.1